Join us at our MarketsandMarkets Orphan Drugs and Rare Diseases Conference in Boston, USA for a groundbreaking exploration of the recent advances in developing life-saving therapies, technologies in diagnosing, and strategies to enhance orphan drug development.
The conference will focus on the wide scope of orphan drug developments, critical issues of elevated pricing, reimbursement & access to patients, and strategies to enhance access to novel diagnostics and effective therapies for rare to ultra–rare diseases.
The event will bring together leading pharmaceutical and biotech companies, government and regulatory authorities, patient advocacy groups, payers, investors, and solution providers. It is an unrivalled opportunity to network and exchange invaluable knowledge with the expert leaders in the rare disease community – patient advocates, policy makers, researchers, clinicians, healthcare professionals, healthcare industry representatives, academics, payers, regulators across the globe.
Have a chance to discuss the newest findings in rare diseases and orphan drugs, helping to shape present and upcoming challenges in drug analysis, allowing participants to interact with industry peers and participate in this scientific conference while staying informed about the most recent developments in the study of rare diseases.
We invite you to join us in pushing the boundaries of innovation, forging collaborative partnerships, and creating a brighter future for the millions living with rare conditions across US and beyond!
President & Chief Executive Officer, Sellas Life Sciences Group, Inc.
Chief Medical Officer, EveryONE Medicines Inc.
Program Director, National Center for Advancing Translational Sciences, National Institutes of Health (NIH/NCATS)
Co-Founder & Executive Director, American Society of Pharmacovigilance
Executive Director, National Niemann-Pick Disease Foundation
Senior Director, Global HEOR Neurology, Alexion Pharmaceuticals, Inc
Director, Global Regulatory Affairs, Sanofi
Patient Engagement Lead, Sanofi
Global Rare Disease Value & Access, Sanofi
Boston, USA
